Call for Papers: CEWIT2017

Call for Papers: The 13th International Conference & Expo on Emerging Technologies for a Smarter World (CEWIT2017)
November 7 & 8, 2017
The Center of Excellence in Wireless and Information Technology (CEWIT) at Stony Brook University
Stony Brook, NY, USA
www.cewit.org/conference2017

CEWIT2017 is the premier international forum for presentations of original research results as well as the exchange and transfer of innovative, end-to-end solutions, applications, and systems of emerging technologies in infrastructure, healthcare, and energy – three of the most critical components of a smarter global world. Specific topics of interest include but are not limited to, the Internet of Things; Cybersecurity; Big Data Analytics and Visualization; Health Technologies and Medical Devices; Smart Energy; and Smart Urban Systems, as well as Technological Applications and Tech Entrepreneurship.

Organized by the NYSTAR-designated New York State Center of Excellence in Wireless and Information Technology (CEWIT), CEWIT2017 is a destination for researchers, innovators, and entrepreneurs, across borders and disciplines, to exchange ideas, build valuable partnerships, and bring cutting-edge technology to the marketplace. The 2017 program will feature a series of research and entrepreneurial-focused tech talks, workshops, and keynote plenaries at CEWIT’s next generation research and educational facility at Stony Brook University.

Abstract Submission Deadline: August 1, 2017
More Information and to Submit Your Contribution: www.cewit.org/conference2017
Contact: 631-216-7000; conference@cewit.org

Annual Applied Research And Development Awards Announced

Awards Support Innovative Research Collaborations Between Academic Faculty and Regional Bioscience Companies

The Center for Biotechnology at Stony Brook University has announced the recipients of the 2017-2018 Applied Research & Development (ARAD) awards. The ARAD Program is designed to help bridge the gap between the early-stage technology discovery and development capabilities of the academic community, and the later-stage commercial development interests of the bioscience industry.

The program currently provides matching funds on a competitive basis to support collaborations between Stony Brook University faculty and New York State corporate partners in all areas of medical biotechnology. The primary interest is in supporting development of technologies that will help companies hit commercially relevant milestones, and that have the potential to positively impact the New York State economy.

Projects supported this year include the furthered development of an ICU temporary pacemaker, a novel Lymphoma treatment, a novel synthetic peptide based therapeutic for Osteoporosis, further development of an fMRI Dynamic Phantom, development of novel vaccines, third generation taxoid based nanomedicine for chemoresistant cancer, development of a polymeric heart valve, a drug delivery technology for treatment of gastrointestinal diseases, and the development of skin brightening agents.

“The Center’s Applied Research and Development Program speaks to the core of what our organization does – collaborate with New York State companies to help them develop commercially promising technologies that will lead to strategic partnerships, investment, corporate revenues, and job creation” said Diane Fabel, Director of Operations for the Center for Biotechnology. “Our academic institutions are incredible resources for bioscience companies to tap into when it comes to technology development, and promoting interactions between the two helps fuel the overall bioscience ecosystem in the region.”

The ARAD Program is part of a suite of programs and services provided by the Center for Biotechnology (CFB) focused on accelerating the development of biomedical technologies in order to have a positive impact on human health and society. The CFB is also the lead administrative institution for the Long Island Bioscience Hub (LIBH) an NIH-designated Research Evaluation and Commercialization Hub (REACH) established with a National Institutes of Health grant in 2015.

2017-2018 Applied Research and Development Awards 

“Synthetic Osteogenic Peptide for Treatment of Osteoporosis” Ajes Life Sciences & Dr. Srinivas Pentyala

“fMRI Dynamic Phantom for Improved Detection of Resting State Brain Networks” ALA Scientific Instruments & Dr. Helmut Strey

“Continued Development of ICU Temporary Pacemaker” Avery Biomedical Inc & Dr. Wei Lin

“Novel Pleiotropic Skin Brightening Agents” Biocogent, LLC & Dr. Sanford Simon

“In vivo Testing of Vaccine Candidates” Codagenix, Inc & Dr. Eckard Wimmer

“A Novel Polymeric Valve for Transcatheter Aortic Valve Replacement” Polynova Cardiovascular, Inc. & Dr. Danny Bluestein

“Imaging the Targeted Delivery of Biologic Agents to the Colon for Local Therapeutic Action” Symbiotic Health Inc. & Dr. Peter M. Smith-Jones

“Eradication of an Oncogenic Herpesvirus as a Novel Intervention for Lymphoma” Theragnostic Technologies, Inc. & Dr. Laurie T. Krug

“Novel Cancer Stem Cell Cytotoxic Agent: Nano-Formulation IND-Enabling Studies” TargaGenix Inc. & Dr. Galina Botchkina

Download a PDF of the press release here.

 

BIO 2016

bio2016c

The Center for Biotechnology team recently ventured out to San Francisco for BIO’s annual International Convention. Through the support of Empire State Development and the Long Island Bioscience Hub, the Center for Biotechnology was able to support six Long Island emerging biotech companies to attend the meeting: Alpha-1 Biologics Corporation, Codagenix, Inc., DepYMed, Inc., iCell Gene Therapeutics, PhD Skin Care LLC and Vela Therapeutics. These companies were joined in the New York Pavilion by more than two dozen other companies and entities representing New York State.

Long Island and New York City regional companies Alpha-1 Biologics, Vela Therapeutics, Intrommune Therapeutics, PainQX, Serendipity Biotech, ENB Therapeutics, and QuickSilver Biosystems all were recipients of grants from Empire State Development and NewYorkBio which also assisted their participation in the event. These companies were tapped to present in the New York Pavilion along with six other companies from upstate New York.

Envisagenics, ENB Therapeutics, PainQx, QuickSilver and Abcombi BioSciences, all New York State Companies, were invited to participate in the BIO 2016 “Start-Up Stadium” which provide start-up companies with the opportunity to pitch to key members of the investment community, venture philanthropy groups, and BIO attendees. The participating investors provided live feedback and judged the sessions.

In addition, six Long Island Bioscience Hub faculty members were invited to participate in the meeting for the first time. These NIH-REACH program supported faculty attended with the goal to learn more about the commercialization process, how it applies to their translational research, and to engage in the partnering process and meet with potential strategic contacts. Center staff met with over 40 strategic partners over the course of the meeting and follow up is underway.

bio2016b

Center for Biotechnology Redesignated by New York State: ‘Unique Time of Change and Growth’

Independently documented economic impact: $1.2 Billion

Jobs created: 1,125

New corporate revenues: $812 Million

Supported additional funding: $238 Million

Center for Biotechnology documented economic impact over recent fifteen-year period

Perhaps it is numbers like these which best illustrate the success CFB has had on the biotechnology industry and economy.

And perhaps they contributed to the redesignation of the CFB as a Center for Advanced Technology for ten years by the New York State Foundation for Science, Technology and Innovation (NYSTAR) as a Center for Advanced Technology (CAT).

The New York State redesignation recognizes the impact of the CFB over 30 years driving innovation toward commercial goals and resulting in accelerated product development cycles “from bench to boardroom to bedside.” It recognizes the key role played by the CFB in facilitating a regional bioscience innovation ecosystem, collaborating with Stony Brook University, Cold Spring Harbor Laboratory, and Brookhaven National Laboratory.

The redesignation by New York State validates all of the work we have done over the last 10-year period to create the foundation for exponential growth. We would not have secured the National Institutes of Health REACH award without it, says Clint Rubin, Director of the Center for Biotechnology.”The REACH designation represents an $8.1M investment in technology development, commercialization, and new company formation. Visionary’s like New York State Senator Kenneth La Valle deserve the credit. They recognized thirty years ago that universities represented a largely untapped pool of innovation and economic potential.

Strikingly, it validates and provides the foundation for the new Long Island Bioscience Hub (LIBH), a CFB-led initiative to formally bring these institutions together to foster technology development, commercialization, and new company formation. The LIBH is a bold step made possible by a partnership with the National Institute of Health REACH initiative (Research Evaluation and Commercialization Hub). The NIH award places the CFB in the national spotlight along with other elite institutions. (Read more on the NIH REACH award here)

“This redesignation occurs in an interesting and changing environment, where varying elements in the regional, state, and national biotech ecosystem are aligning. There is a confluence of events and issues that are creating a unique opportunity to build the biotech economy in the region and across the State.” Commented Diane Fabel, Director of Operations, CFB. “We have learned a lot about the process of moving academic innovation into the commercial sector over time. And there have been such tremendous scientific advances recently that represent new commercial opportunities and life saving technologies. There is still much to learn and do, and it is an incredibly exciting time to be doing it.